SCHEMBL1269422

SCHEMBL1269422

CCOC(=O)c1nc(NC(C)=O)ccc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.49
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPK8 P45983 1/20 0.47
ALDH1A1 P00352 4/20 0.46
HPGD P15428 1/20 0.46
CYP1A2 P05177 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CYP2C9 P11712 2/20 0.44
STAT1 P42224 1/20 0.44
CYP2C19 P33261 1/20 0.44
GAA P10253 1/20 0.44
MCL1 Q07820 1/20 0.43
ALOX15 P16050 1/20 0.43
TARBP2 Q15633 1/20 0.42
KDM4E B2RXH2 3/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29598124 0.85 MAPT (0.46) TSHRMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL4908919 0.79 TARBP2 (0.48) TSHRMEN1KMT2AMAPTALDH1A1
SCHEMBL19715739 0.79 TARBP2 (0.48) TSHRKMT2AMAPTALDH1A1CYP1A2
SCHEMBL1268686 0.79 LMNA (0.51) KMT2ASMN1; SMN2MAPK8ALDH1A1CYP1A2
SCHEMBL29424937 0.79 LMNA (0.51) KMT2ASMN1; SMN2MAPK8ALDH1A1CYP1A2
SCHEMBL18132220 0.77 CYP1A2 (0.59) TSHRMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL20935165 0.77 MAPK8 (0.56) MEN1KMT2AMAPTMAPK8CYP1A2
SCHEMBL4903491 0.76 TARBP2 (0.46) TSHRKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL1269540 0.76 ALDH1A1 (0.46) TSHRMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL30200423 0.76 TARBP2 (0.46) TSHRKMT2AMAPTALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG TSHR 501/4885MEN1 4841/4885KMT2A 1448/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG TSHR 501/4885MEN1 4841/4885KMT2A 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.